Clinical trials: Epilepsy, Partial
Seizures
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
- Trial name
- NCT04686786
- Testing
- CVL-865
- Where
- 56 sites in United States, Australia and 5 more
- Volunteers
- 105 people
- Sponsor
- AbbVie
Epilepsy
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic…
- Trial name
- ALEX-MT (NCT00520741)
- Testing
- Lacosamide
- Where
- 158 sites in United States, Australia and 11 more
- Volunteers
- 426 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.
The goal of the present study is to evaluate ("screen") a large number (12) of different dual therapies of perampanel + another AED ("PMP+") for a large, 75-100% seizure frequency reduction.
- Trial name
- NCT02727101
- Testing
- perampanel
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mid-Atlantic Epilepsy and Sleep Center, LLC
Schizophrenia, Schizoaffective Disorder
Donepezil Double Blind Trial for ECT Memory Disfunction
This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00465283
- Testing
- Donepezil
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- BeerYaakov Mental Health Center
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization…
- Trial name
- NCT03083665
- Testing
- Brivaracetam
- Where
- 94 sites in China, Japan and 5 more
- Volunteers
- 449 people
- Sponsor
- UCB Biopharma SRL
Epilepsy, Partial
An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy
observational, non-interventional study in 120 patients with drug-resistant partial epilepsy, comprising two phases: a 3-month retrospective and a 6-month prospective.
- Trial name
- NCT01332539
- Testing
- no intervention
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial Onset Seizures
A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
The purpose of this study is to evaluate the efficacy and safety of 200 and 400 mg/day of orally administered Lacosamide as adjunctive therapy compared with placebo in Japanese and Chinese adults with uncontrolled Partial-Onset…
- Trial name
- NCT01710657
- Testing
- Lacosamide 50 mg, Lacosamide 100 mg
- Where
- 76 sites in China, Japan
- Volunteers
- 548 people
- Sponsor
- UCB Pharma SA
Drug-Resistant Epilepsy, Epilepsy
Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
The goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy.
- Conditions
- Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities
- Trial name
- NCT07680842
- Testing
- Target optimization using LIFU, Serial LIFU stimulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Epilepsies, Partial
MRI in Autosomal Dominant Partial Epilepsy With Auditory Features
This study will examine the possible structural and functional abnormalities in patients with an inherited form of epilepsy. It will use magnetic resonance imaging (MRI).
- Trial name
- NCT00072813
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy
The purpose of the study is to evaluate the effectiveness and safety of topiramate as add-on therapy in patients with difficult to control partial onset seizures who are taking one or two standard anti-epileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236730
- Testing
- topiramate
- Volunteers
- 178 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Temporal Lobe Epilepsy
Closed Loop Auditory Stimulus in Sleep and epilepsY
This is a single-centre pilot study of a non-invasive auditory stimulation during sleep in participants with temporal lobe epilepsy.
- Trial name
- CLASSY (NCT05159609)
- Testing
- Closed loop auditory stimulus
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cardiff and Vale University Health Board
Epilepsies, Partial
Drug Use Investigation Of Gabapentin
The objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00567268
- Testing
- Gabapentin
- Volunteers
- 1,273 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug-resistant Focal Epilepsy, Epilepsy
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy
Laser Induced Interstitial Thermal Therapy (LITT) is a "minimally invasive" procedure that uses the heat generated by a laser light (65°) to destroy brain lesions by coagulation leading to lesion necrosis under real-time MRI…
- Conditions
- Drug-resistant Focal Epilepsy, Epilepsy, Epilepsies, Focal, Focal Epilepsy
- Trial name
- EPILITT (NCT05198882)
- Testing
- Laser technology for intracerebral thermocoagulation
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Partial Seizure
An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.
An open label, balanced, randomized, 3×3 latin square design comparing of Brivaracetam sustained-release tablets and Brivaracetam tablets in the oral comparative pharmacokinetic(PK) study in Chinese healthy adult subjects under…
- Trial name
- NCT05622370
- Testing
- Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Epilepsies, Partial
Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study
The purpose of this pilot study is to describe the relationship of regional cerebral oximetry and cytoximetry, measured using near-infrared spectroscopy, with seizure activity in the periictal period in children with epilepsy.
- Trial name
- NCT03054961
- Testing
- Near-infrared spectroscopy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Medical College of Wisconsin
Epilepsy
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource…
- Trial name
- NCT01728077
- Testing
- Brivaracetam
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 26 people
- Sponsor
- UCB Pharma SA
Epilepsy
Controlled Randomized Vagus Nerve Stimulation (VNS) Therapy Versus Resection (CoRaVNStiR)
Background: There are a variety of treatment options for medically refractory medial temporal lobe epilepsy. Evidence from randomized trials indicates vagus nerve stimulation therapy can be used as a proven therapy for medically…
- Trial name
- CoRaVNStiR (NCT02089243)
- Testing
- Vagus nerve stimulation therapy, Resective surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xijing Hospital
Epilepsy, Temporal Lobe
Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy
The goal is to provide a novel therapeutic option for temporal lobe epilepsy patients when focal impaired awareness seizures cannot be stopped by medications, surgical or laser ablation, or by neurostimulation.
- Trial name
- START (NCT04897776)
- Testing
- Central Thalamic Stimulation, Hippocampal Stimulation
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Epilepsy, Seizures
A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy
The purpose of this study is to evaluate the effectiveness and safety of topiramate (an antiepileptic medication) in patients with epilepsy.
- Trial name
- NCT00266591
- Testing
- topiramate
- Volunteers
- 51 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.